Cingulate Achieves Key Manufacturing Milestone in the Development of its ADHD Drug CTx-1301 in Preparation for FDA Marketing Clearance

June 25, 2024

https://www.globenewswire.com/news-release/2024/06/25/2903886/0/en/Cingulate-Achieves-Key-Manufacturing-Milestone-in-the-Development-of-its-ADHD-Drug-CTx-1301-in-Preparation-for-FDA-Marketing-Clearance.html

Twelve Required Registration Batches Completed
New Drug Application Being Prepped for Submission

KANSAS CITY, Kan., June 25, 2024 (GLOBE NEWSWIRE) — In alignment with U.S. Food and Drug Administration (FDA) requirements, Cingulate Inc. (NASDAQ:CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, announced today that it has completed the manufacturing of its twelve registration batches for its lead asset CTx-1301 (dexmethylphenidate) for the treatment of Attention Deficit Hyperactivity Disorder (ADHD).

Read more at globenewswire.com

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.